InnoCan Pharma Corporation
INNPF
$4.95
-$0.03-0.60%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.99M | 6.82M | 7.01M | 7.80M | 5.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.99M | 6.82M | 7.01M | 7.80M | 5.40M |
| Cost of Revenue | 558.00K | 631.00K | 811.00K | 681.00K | 992.00K |
| Gross Profit | 4.43M | 6.19M | 6.20M | 7.12M | 4.41M |
| SG&A Expenses | 5.19M | 6.99M | 5.62M | 6.45M | 5.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.91M | 8.04M | 6.61M | 7.31M | 6.32M |
| Operating Income | -922.00K | -1.22M | 396.00K | 489.00K | -919.00K |
| Income Before Tax | 1.59M | -1.43M | -109.00K | 33.00K | 3.00K |
| Income Tax Expenses | -262.00K | 220.00K | 206.00K | 262.00K | 51.00K |
| Earnings from Continuing Operations | 1.86M | -1.65M | -315.00K | -229.00K | -48.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 140.00K | -295.00K | -275.00K | -353.00K | -66.00K |
| Net Income | 2.00M | -1.95M | -590.00K | -582.00K | -114.00K |
| EBIT | -922.00K | -1.22M | 396.00K | 489.00K | -919.00K |
| EBITDA | -910.00K | -1.21M | 405.00K | 499.00K | -913.00K |
| EPS Basic | 0.45 | -0.43 | -0.13 | -0.13 | -0.03 |
| Normalized Basic EPS | 0.17 | -0.25 | -0.06 | -0.07 | -0.01 |
| EPS Diluted | 0.45 | -0.43 | -0.13 | -0.13 | -0.03 |
| Normalized Diluted EPS | 0.17 | -0.25 | -0.06 | -0.07 | -0.01 |
| Average Basic Shares Outstanding | 4.48M | 4.50M | 4.50M | 4.47M | 4.42M |
| Average Diluted Shares Outstanding | 4.48M | 4.50M | 4.50M | 4.47M | 4.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |